- Home
- A-Z Publications
- Current Medicinal Chemistry
- Previous Issues
- Volume 19, Issue 9, 2012
Current Medicinal Chemistry - Volume 19, Issue 9, 2012
Volume 19, Issue 9, 2012
-
-
Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Authors: Guido Cavaletti and Barbara SlusherGlutamate is a highly abundant excitatory neurotransmitter in the central nervous system residing in vesicles within chemical synapses. Once a nerve impulse triggers the release of glutamate from the pre-synaptic cell, it binds to and activates both ionotropic (ion channel- forming) and metabotropic (G protein-activating) glutamate receptors on the opposing post-synaptic cell. Subsequently glutamate transporters, locali Read More
-
-
-
The Role of Glutamate in Diabetic and in Chemotherapy Induced Peripheral Neuropathies and its Regulation by Glutamate Carboxypeptidase II
Authors: V. A. Carozzi and C. CeresaGlutamate has been implicated in the pathogenesis of several diseases on the central nervous system, but recent studies have also suggested that it can be involved also in the onset and course of peripheral neuropathies. Given the increasing evidence of this possibility, several attempts have been performed in order to modulate its activity. Among them, glutamate carboxypeptidase II (GCP II) inhibition demonstrated promisin Read More
-
-
-
The Glutamatergic Neurotransmission in the Central Nervous System
Authors: P. Marmiroli and G. CavalettiGlutamate is one of the major neurotrasmitters in mammalian brain and changes in its concentration have been associated with a number of neurological disorders, including neurodegenerative, cerebrovascular diseases and epilepsy. Moreover, recently a possible role for glutamatergic system dysfunction has been suggested also in the peripheral nervous system. This chapter will revise the current knowledge in the distr Read More
-
-
-
Tissue Distribution of Glutamate Carboxypeptidase II (GCPII) with a Focus on the Central and Peripheral Nervous System
Authors: P. Marmiroli, B. Slusher and G. CavalettiGlutamate carboxypeptidase II, also known as prostate specific membrane antigen or folate hydrolase I, is a type II transmembrane 750 amino acid membrane-bound glycoprotein, with a molecular weight in the human form of approximately 100 kDa and a demonstrated metallopeptidase activity. At the synaptic level it hydrolyzes N-acetylaspartylglutamate to N-acetyl-aspartate and glutamate. Its localization in the animal a Read More
-
-
-
Structure-Activity Relationships of Glutamate Carboxypeptidase II (GCPII) Inhibitors
Authors: D. V. Ferraris, K. Shukla and T. TsukamotoGlutamate carboxypeptidase II (GCPII, EC 3.4.17.21) is a zinc metallopeptidase that hydrolyzes N-acetylaspartylglutamate (NAAG) into N-acetylaspartate (NAA) and glutamate in the nervous system. Inhibition of GCPII has the potential to reduce extracellular glutamate and represents an opportune target for treating neurological disorders in which excess glutamate is considered pathogenic. Furthermore, GCPII was fou Read More
-
-
-
Glutamate and Multiple Sclerosis
Authors: M. Frigo, M. G. Cogo, M. L. Fusco, M. Gardinetti and B. FrigeniMultiple sclerosis (MS) has been considered for a long time a typical inflammatory demyelinating disease of the central nervous system due to autoimmunity targeting oligodendrocytes with sparing of axons until advanced stages of the disease. For this reason, most of the earliest experimental studies focused on the role of cytokines and chemokines at the site of oligodendrocytes loss and on the importance in MS Read More
-
-
-
Glutamate Carboxypeptidase II: An Overview of Structural Studies and Their Importance for Structure-Based Drug Design and Deciphering the Reaction Mechanism of the Enzyme
Authors: J. Pavlicek, J. Ptacek and C. BarinkaRecent years witnessed rapid expansion of our knowledge about structural features of human glutamate carboxypeptidase II (GCPII). There are over thirty X-ray structures of human GCPII (and of its close ortholog GCPIII) publicly available at present. They include structures of ligand-free wild-type enzymes, complexes of wild-type GCPII/GCPIII with structurally diversified inhibitors as well as complexes of the GCPII(E424A) i Read More
-
-
-
Assessing Glutamatergic Function and Dysfunction in Peripheral Tissues
Authors: L. Tremolizzo, G. Sala, C. P. Zoia and C. FerrareseGlutamate is the major mediator of excitatory signaling in the mammalian central nervous system (CNS) and it has recently been described to have a central role in the transduction of sensory input in the peripheral nervous system (PNS), too. However, functional glutamatergic systems are expressed by peripheral non-neural tissues as well, such as heart, kidney, lungs, ovary, testis, blood and skin. Interestingly, glutamatergi Read More
-
-
-
GCPII Variants, Paralogs and Orthologs
Authors: K. Hlouchova, V. Navratil, J. Tykvart, P. Sacha and J. KonvalinkaGlutamate carboxypeptidase II (GCPII) and its splice variants, paralogs and human homologs represent a family of proteins with diverse tissue distribution, cellular localization and largely unknown function which have been explored only recently. While GCPII itself has been thoroughly studied from different perspectives, as clearly documented in this series of reviews, very little is known about other members of its famil Read More
-
-
-
The Role of Glutamate Signaling in Pain Processes and its Regulation by GCP II Inhibition
Authors: K. M. Wozniak, C. Rojas, Y. Wu and B. S. SlusherGlutamate is the predominant excitatory neurotransmitter used by primary afferent synapses and neurons in the spinal cord dorsal horn. Glutamate and glutamate receptors are also located in areas of the brain, spinal cord and periphery that are involved in pain sensation and transmission. Not surprisingly, glutamate receptors have been an attractive target for new pain therapies. However, their widespread di Read More
-
-
-
Glutamate in CNS Neurodegeneration and Cognition and its Regulation by GCPII Inhibition
Authors: K. A. Rahn, B. S. Slusher and A. I. KaplinGlutamate, first identified in 1866, is the primary excitatory neurotransmitter in the brain. While it is critically important in many highly regulated cortical functions such as learning and memory, glutamate can be much like the magic the Sorcerer's Apprentice used in Goethe's poem: when conjured under unregulated conditions glutamate can get quickly out of control and lead to deleterious consequences. Two broad types Read More
-
-
-
GCPII Imaging and Cancer
Authors: C. A. Foss, R. C. Mease, S. Y. Cho, H. J. Kim and M. G. PomperGlutamate carboxypeptidase II (GCPII) in the central nervous system is referred to as the prostate-specific membrane antigen (PSMA) in the periphery. PSMA serves as a target for imaging and treatment of prostate cancer and because of its expression in solid tumor neovasculature has the potential to be used in this regard for other malignancies as well. An overview of GCPII/PSMA in cancer, as well as a discussion of im Read More
-
-
-
NAAG, NMDA Receptor and Psychosis
Authors: Richard Bergeron and Joseph T. CoyleAt central synapses, glutamate is the main excitatory neurotransmitter. Once released from presynaptic terminals, glutamate activates a number of different glutamatergic receptors one of which is the ligand gated ionophore glutamatergic subtype N-methyl-Daspartate receptors (NMDARs). NMDARs play a crucial role in controlling various determinants of synaptic function. Nacetylaspartylglutamate (NAAG) is the most preval Read More
-
-
-
Recognition of Nucleic Acid Ligands by Toll-Like Receptors 7/8: Importance of Chemical Modification
Authors: Hui Yu, Zhanli Wang, Gang Sun and Yongchun YuToll-like receptors 7 and 8 (TLR7/8), known as pattern recognition receptors (PRR), are currently viewed as important targets for the development of new therapies for multiple diseases. Therefore, manipulating the immune response by using TLR7/8 agonists or antagonists might be of therapeutic value. Nucleic acid-like structures are well-known TLR7/8 ligands, such as single-stranded RNA (ssRNA), small interfering RN Read More
-
-
-
Azole Antimycotics - A Highway to New Drugs or a Dead End?
Authors: R. Musiol and W. KowalczykAzole antimycotics are a well-known and important class of agents that are used in hospital practice, everyday health care, veterinary medicine and for crop protection. The era of azole fungicides began with the breakthrough of chlormidazole roughly 50 years ago. Since then, more than 20 drugs of this group, including triazoles, have been brought to the market. The specific chemical structure and mechanism of the action Read More
-
-
-
Non-Alcoholic Steatohepatitis: What Can We Learn from Animal Models?
Authors: C. C. Almonacid-Urrego, S. Sanchez-Campos, M. J. Tunon and J. Gonzalez-GallegoNon-alcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver function and correlates with central adiposity, obesity, insulin resistance, the metabolic syndrome and type 2 diabetes mellitus. The pathological spectrum of NAFLD ranges from fatty liver to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and even hepatocellular carcinoma. Though NAFLD and NASH are bec Read More
-
-
-
Update on the Slow Delayed Rectifier Potassium Current (IKs): Role in Modulating Cardiac Function
Authors: Zhenzhen Liu, Lupei Du and Minyong LiThe slow delayed rectifier current (IKs) is the slow component of cardiac delayed rectifier current and is critical for the late phase repolarization of cardiac action potential. This current is also an important target for Sympathetic Nervous System (SNS) to regulate the cardiac electivity to accommodate to heart rate alterations in response to exercise or emotional stress and can be up-regulated by β- adrenergic or other si Read More
-
Volumes & issues
-
Volume 32 (2025)
-
Volume 31 (2024)
-
Volume 30 (2023)
-
Volume 29 (2022)
-
Volume 28 (2021)
-
Volume 27 (2020)
-
Volume 26 (2019)
-
Volume 25 (2018)
-
Volume 24 (2017)
-
Volume 23 (2016)
-
Volume 22 (2015)
-
Volume 21 (2014)
-
Volume 20 (2013)
-
Volume 19 (2012)
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 18 (2011)
-
Volume 17 (2010)
-
Volume 16 (2009)
-
Volume 15 (2008)
-
Volume 14 (2007)
-
Volume 13 (2006)
-
Volume 12 (2005)
-
Volume 11 (2004)
-
Volume 10 (2003)
-
Volume 9 (2002)
-
Volume 8 (2001)
-
Volume 7 (2000)
Most Read This Month
Article
content/journals/cmc
Journal
10
5
false
en
